Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice

Chiara Domenicale 1,†, Daniela Mercatelli 1,2,†, Federica Albanese 1, Salvatore Novello 1,3, Katia Varani 4 and Michele Morari 1,*

1 Department of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, Italy; chiara.domenicale@unife.it (C.D.); daniela.mercatelli@unife.it (D.M.); federica.albanese@unife.it (F.A.); salvatore.novello@epfl.ch (S.N.)
2 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44121 Ferrara, Italy
3 Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
4 Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; fabrizio.vincenzi@unife.it (F.V.); katia.varani@unife.it (K.V.)
* Correspondence: m.morari@unife.it
† These authors contributed equally to this work.

Abstract: The G2019S mutation in leucine rich-repeat kinase 2 (LRRK2) is a major cause of familial Parkinson’s disease. We previously reported that G2019S knock-in mice manifest dopamine transporter dysfunction and phosphoSerine129 α-synuclein (pSer129 α-syn) immunoreactivity elevation at 12 months of age, which might represent pathological events leading to neuronal degeneration. Here, the time-dependence of these changes was monitored in the striatum of 6, 9, 12, 18 and 23-month-old G2019S KI mice and wild-type controls using DA uptake assay, Western analysis and immunohistochemistry. Western analysis showed elevation of membrane dopamine transporter (DAT) levels at 9 and 12 months of age, along with a reduction of vesicular monoamine transporter 2 (VMAT2) levels at 12 months. DAT uptake was abnormally elevated from 9 to up to 18 months. DAT and VMAT2 level changes were specific to the G2019S mutation since they were not observed in LRRK2 kinase-dead or knock-out mice. Nonetheless, dysfunctional DAT uptake was not normalized by acute pharmacological inhibition of LRRK2 kinase activity with MLi-2. Immunoblot analysis showed elevation of pSer129 α-syn levels in the striatum of 12-month-old G2019S KI mice, which, however, was not confirmed by immunohistochemical analysis. Instead, total α-syn immunoreactivity was found elevated in the striatum of 23-month-old LRRK2 knock-out mice. These data indicate mild changes in DA transporters and α-syn metabolism in the striatum of 12-month-old G2019S KI mice whose pathological relevance remains to be established.

Keywords: DAT; G2019S knock-in; [3H]-DA uptake; D1994S kinase-dead; LRRK2; MLi-2; pSer129 α-synuclein; Parkinson’s disease; VMAT2

1. Introduction

The c.6055G>A transition in the leucine-rich-repeat kinase 2 (LRRK2) gene results in the G2019S substitution in the LRRK2 protein, which is associated with familial, autosomal dominant forms of Parkinson’s Disease (PD) and represents a risk factor for idiopathic PD [1,2]. LRRK2 is a multidomain protein encompassing a kinase and a GTPase domain surrounded by protein–protein interaction domains [3,4]. The G2019S mutation causes a 2–3-fold increase in kinase activity which is instrumental to LRRK2 neurotoxicity in vitro [5–7] and in vivo [8–10]. LRRK2 G2019S-associated PD and idiopathic PD share clinical and neuropathological features. Indeed, they are characterized by hypokinetic symptoms, nigrostriatal dopamine (DA) neuron degeneration and Lewy body pathology [1,11].
although the neuropathology in the LRRK2 brains appears more heterogeneous than in idiopathic PD brains [1]. Several rodent models have been developed to recapitulate clinical and neuropathological features of PD [12], although, in most cases, the outcome has been disappointing. In fact, G2019S knock-in (KI) mice [13,14], human G2019S (hG2019S) LRRK2 BAC overexpressing mice [15–17], and rats [18–20] do not show nigrostriatal degeneration. Only in 12–21-month-old mice overexpressing hG2019S under the PDGF promoter was a 18–50% neuronal loss in SNc consistently reported [21,22]. Nonetheless, abnormalities in DA neuron morphology, DA homeostasis, or transmission have been observed in G2019S LRRK2 KI and transgenic rodents, which have been viewed as early signs of DA neuron demise. Consistent with this view, G2019S KI mice were found to be more prone to develop nigrostriatal degeneration after exposure to Parkinsonian triggers, such as mitochondrial toxins rotenone or MPTP [23,24], genetic or virally-mediated overexpression of mutant α-synuclein (α-syn) [25,26], or injection of preformed fibrils (PFFs) of α-syn [27]. In this context, we reported that G2019S KI mice showed age-dependent elevation of striatal levels and activity of the membrane DA transporter (DAT) along with reduction of striatal levels of the vesicular monoamine transporter type 2 (VMAT2) [14]. It has long been recognized that abnormal synaptic handling of DA, e.g., resulting from DA transporter dysfunction, can result in accumulation of intrasynaptic DA, build-up of DA metabolism byproducts and toxicity of DA terminals [28,29]. DA accumulation resulting from DAT upregulation [30] and/or VMAT2 deletion [31,32] is associated with DA neuron loss, whereas VMAT2 over-expression is neuroprotective [32,33]. Reduced expression of VMAT2 via RNAi in rats [32] leads to the appearance of a Parkinsonian phenotype and foci of loss of tyrosine hydroxylase (TH) positive terminals in striatum, and is associated with increased phosphorylation of α-syn at Serine 129 (pSer129 α-syn) in SNc, which can be viewed as an early index of neuronal toxicity [34]. Interestingly, we also reported that DAT and VMAT2 changes in the striatum of 12-month-old G2019S KI mice were accompanied by an increase of pSer129 αsyn inclusions in striatum and SNc [14]. In this follow-up study, to correlate changes of DA transporters with α-syn inclusions, striatal DAT and VMAT2 levels and activity were monitored along with endogenous pSer129 α-syn immunoreactivity in G2019S KI mice of 6, 9, 18 and 23 months and age-matched WT controls. To further investigate the role of LRRK2 kinase activity in DAT changes, mice bearing a kinase-dead mutation (KD mice) and mice with constitutive deletion of LRRK2 (KO mice) were used. Moreover, the LRRK2 inhibitor MLi-2 was acutely administered to reveal whether kinase activity sustains the changes of DAT activity.

2. Materials and Methods

2.1. Animals

Male homozygous LRRK2 G2019S KI, LRRK2 KO and D1994S KI mice (kinase-dead, KD mice), backcrossed on a C57Bl/6J background, were used in comparison with WT control mice [14,35–37]. Colonies were raised at the animal facility (LARP) of the University of Ferrara, under regular lighting conditions (12 h light/dark cycle) with food and water ad libitum. Founders were obtained from Mayo Clinic (Jacksonville, FL, USA) (LRRK2 KO mice) [38] and from Novartis Institutes for BioMedical research (Novartis Pharma AG, Basel, Switzerland) (G2019S KI and KD mice) [39]. Experimental procedures were approved by the Ethical Committee of the University of Ferrara and the Italian Ministry of Health (licenses n. 102/2017-PR and 134/2017-PR).

2.2. Western Blot Analysis

Mice were anesthetized and euthanized by cervical dislocation. Striata were processed as previously described [37,40] Samples were tested for the following primary antibodies: rabbit anti-DAT (D6944, 1:1000; Sigma Aldrich, Saint Louis, MO, USA), rabbit anti-VMAT2 (V9014, 1:300; Sigma Aldrich, Saint Louis, MO, USA), rabbit anti-pSer129 α-syn (ab51253, 1:2000; Abcam, Cambridge, UK), rabbit anti-α-syn (ab212184, 1:1000; Abcam, Cambridge, UK), and anti-rabbit GAPDH (PA1-988, 1:1000; Thermo Scientific, Carlsbad, CA, USA).
After incubation with secondary antibody (goat anti-rabbit IgG HRP-conjugate 12–348, 1:4000; Merck Millipore, Darmstadt, Germany), immunoreactive proteins were visualized by enhanced chemiluminescence (ECL) detection kit (PierceTM BCA Protein Assay Kit, Thermo Scientific or ECL+, GE Healthcare) and images acquired and quantified using the ChemiDoc MP System and the ImageLab Software (Bio-Rad, Hercules, CA, USA). Data were analyzed by densitometry, and the optical density of specific target protein bands was normalized to the housekeeper protein level.

2.3. DA Uptake Assay

Mice were anesthetized and euthanized by cervical dislocation. Striatal synaptosomes were obtained and DAT activity assay carried out as previously described [14]. Essentially, synaptosomes were incubated for 5 min at 37 °C with 20 nM [3H]-DA isotopically diluted with varying concentrations of unlabeled DA to obtain final DA concentrations in the 20–2000 nM range. Non-specific DA uptake was evaluated in the presence of 5 µM GBR-12783 dihydrochloride (Tocris Bioscience, Bristol, UK). The filter-bound radioactivity was counted using a PerkinElmer Tri Carb 2810 TR scintillation counter (PerkinElmer, Waltham, MA, USA). Specific DA uptake was expressed as pmol/mg protein/min [41], and kinetic parameters (Vmax and Km) were determined using Prism 5.0 (Graph-Pad Software Inc., San Diego, CA, USA).

2.4. VMAT2 Activity Assay

Whole-brain synaptic vesicles were obtained, and VMAT2 activity assay was carried out as previously described [14]. Synaptic vesicles were incubated for 5 min at 37 °C with 20 nM [3H]-DA isotopically diluted with varying concentrations of unlabeled DA. Radioactivity was counted with a PerkinElmer Tri Carb 2810 TR scintillation counter.

2.5. Immunohistochemistry

Mice were deeply anesthetized with isoflurane and transcardially perfused with 4% paraformaldehyde in Phosphate Buffer Solution (PBS; 0.1 M, pH 7.4). Brains were removed, transferred to a 30% sucrose solution in PBS for cryoprotection and then stored at −80 °C. Fifty micrometer free-floating sections of striatum (AP from +1.42 to +0.14 from bregma) [42] were rinsed in PBS incubated for 30 min at room temperature with a blocking solution (PBS + BSA 1:50 + Triton X100 0.3%) and then incubated with a rabbit polyclonal antibody raised against total α-syn (ab52168; 1:250 in BSA 1% PBST; Abcam, Cambridge, UK), pSer129 α-syn (ab51253; 1:200 in BSA 1% PBST; Abcam, Cambridge, UK) or DAT (ab184451; 1:300 in BSA 1% PBST; Abcam, Cambridge, UK) overnight at room temperature. Sections were then rinsed and incubated with an anti-rabbit HRP-conjugated secondary antibody (ab6721, 1:500 in BSA 1% PBST; Abcam, Cambridge UK) and revealed by a DAB substrate kit (ab64238, Abcam, Cambridge, UK). Sections were mounted on gelatinized slides, dehydrated and coverslipped for further analysis. Images were taken at 2.5× magnification with a Leica DM6B motorized microscope (Leica Microsystems, Milan, Italy), and optical density was determined offline with ImageJ software.

2.6. Drugs

MLi-2 was purchased from Carbosynth Limited (Compton, Berkshire, UK) and was dissolved in 4% DMSO and 30% hydroxypropyl β-cyclodextrin.

2.7. Data Presentation and Statistical Analysis

Data are expressed as mean ± SEM (standard error of the mean) of n mice. Statistical analysis was implemented in Graphpad Prism 8.4.3 (GraphPad; LaJolla, CA, USA). The Student t-test, two-tailed for unpaired data, was used to compare two groups; in the remaining cases, one-way or two-way ANOVA followed by the Tukey test for multiple comparisons was used. Outliers were identified using the ROUT method implemented
in Graphpad Prism 8.4.3 (GraphPad; LaJolla, CA, USA). *p < 0.05 values were considered statistically significant.

3. Results

3.1. Time-Dependent DAT Dysfunction in G2019S KI Mice

DAT level and activity were measured in striatal lysates from 6, 9, 12 and 18-month-old G2019S KI and age-matched WT mice (Figure 1). Immunoblot analysis revealed no genotype difference in DAT levels in 6-month-old mice (Figure 1A). Conversely, an increase was observed in 9-month-old (+23%, t = 4.36, df = 10, p = 0.0015; Figure 1B) and 12-month-old (+20%, t = 2.89, df = 10, p = 0.0159; Figure 1C) G2019S KI mice compared to WT controls. Such difference, however, disappeared at 18 months (Figure 1D). Whether changes in DAT levels were accompanied by changes in [3H]-DA uptake kinetics was investigated next (Figure 2). Affinity (Km) and maximal transport rate (Vmax) were similar between G2019S KI and WT mice at 6 months of age (Km 78.04 ± 3.35 vs. 83.01 ± 5.45 nM, Vmax 24.01 ± 1.82 vs. 23.08 ± 0.92 nM, respectively) (Figure 2A). Conversely, a significant 24% increase of Vmax was found in 9-month-old G2019S KI mice compared to age-matched WT controls (27.54 ± 1.18 vs. 22.25 ± 0.99 pmol/mg prot/min, respectively, t = 2.99, df = 6, p = 0.0242) which was not accompanied by changes of Km (79.75 ± 8.46 vs. 69.61 ± 8.85 nM, respectively) (Figure 2B). Likewise, 12-month-old G2019S KI mice showed a 62% increased of Vmax compared to age-matched WT controls (32.02 ± 0.71 vs. 19.75 ± 1.22 pmol/mg prot/min, respectively, t = 8.26, df = 6, p = 0.0020) without changes in Km (69.78 ± 6.67 vs. 67.99 ± 9.15 nM, respectively) (Figure 2C). At 18 months, Vmax was slightly but still significantly higher (+15%) in G2019S KI mice compared to age-matched WT controls (34.70 ± 1.02 vs. 30.27 ± 1.25 pmol/mg prot/min, respectively, t = 2.73, df = 6, p = 0.0342) whereas Km remained unchanged (75.45 ± 6.48 vs. 76.07 ± 4.29 nM, respectively) (Figure 2D).

Figure 1. DAT levels are transiently elevated in G2019S KI mice. Western blot analysis of DAT levels in the striatum of 6-month-old (A), 9-month-old (B), 12-month-old (C) and 18-month-old (D) G2019S KI mice and age-matched WT controls. Data are expressed as mean ± SEM of n = 6 mice per group. Statistical analysis was performed using the Student t-test, two-tailed for unpaired data. *p < 0.05, different from WT.
Figure 1. DAT levels are transiently elevated in G2019S KI mice. Since immunoblot data suggested that the increase of DAT levels relied on the G2019S mutation, the possibility was tested that the abnormal increase of DAT activity observed in G2019S KI mice was sustained by ongoing LRRK2 kinase activity. [43]. MLi-2 caused a 75% reduction of pSer1292 LRRK2 levels (t = 8.838, p < 0.0001; Figure 3C) without affecting total protein levels (Figure 3D), indicating that MLi-2 impaired striatal LRRK2 kinase activity.

3.2. DAT Abnormalities Are Associated with the G2019S Mutation but Independent of Ongoing LRRK2 Kinase Activity

To verify whether the alterations of DAT levels observed in G2019S KI mice were specifically related to the G2019S mutation, striatal DAT levels were measured in a different cohort of 12-month-old G2019S KI mice in comparison with age-matched LRRK2 KO, KD and WT mice (Figure 3A). Immunoblot analysis revealed changes across genotypes (F(3,20) = 4.02, p = 0.0216), and confirmed the elevation of DAT levels in G2019S KI mice (+46%). Conversely, no changes were observed in LRRK2 KO and KD mice compared to WT controls.

Dysfunctional DAT activity in G2019S KI mice appears at 9 months of age. Kinetic analysis of [3H]-DA uptake in synaptosomes were performed in the striata of 6-month-old (A), 9-month-old (B), 12-month-old (C) and 18-month-old (D) G2019S KI mice versus age-matched WT controls. Data are expressed as mean ± SEM of n = 4 mice per group. Statistical analysis was performed using the Student t-test, two-tailed for unpaired data. * p < 0.05, different from WT mice.
VMAT2 Dysfunction in G2019S KI Mice

VMAT2 protein levels were analysed in the striatum of 6, 9, 12 and 18-month-old WT and G2019S KI mice (Figure 4). VMAT2 levels were similar between genotypes in 6-month-old and 9-month-old mice (Figure 4A,B), whereas a 53% decrease was found in 12-month-old G2019S KI mice ($t = 9.806$, df = 10, $p < 0.0001$; Figure 4C) [14]. VMAT2 protein levels were similar between genotypes at 18 months (Figure 4D). To investigate the LRRK2
kinase dependence of the effect observed, VMAT2 levels were measured in G2019S KI mice in comparison with age-matched LRRK2 KD, KO and WT mice. Marked (−55%) reduction of VMAT2 levels was confirmed in the new cohort of G2019S mice, whereas no changes were observed in KD and KO mice (F_{3,20} = 6.487, \( p = 0.0030 \); Figure 4E). VMAT2 uptake activity was then analysed in a whole-brain synaptic vesicle preparation of 9-month-old and 18-month-old mice (Figure 5). The analysis of [^3]H-DA uptake kinetics revealed no difference of Km and Vmax between G2019S KI and WT mice at 9 months (Km 352.10 ± 33.80 vs. 366.40 ± 21.00 nM, Vmax 44.31 ± 2.70 vs. 41.93 ± 1.89 nM, respectively) (Figure 5A) or 18 months (Km 379.6 ± 20.0 vs. 359.6 ± 15.5 nM, Vmax 40.70 ± 3.05 vs. 44.78 ± 1.18 nM, respectively) (Figure 5B).

**Figure 4.** The reduction of VMAT2 levels in G2019S KI mice appears at 12 months and is associated with the G2019S mutation. Western blot analysis of VMAT2 levels in the striatum of 6-month-old (A), 9-month-old (B), 12-month-old (C) and 18-month-old (D) G2019S KI mice versus age-matched WT controls, and representative blots. (E) Western blot analysis of VMAT2 levels in the striatum of 12-month-old G2019S KI mice versus age-matched LRRK2 KO, KD and WT mice, and representative blots. Data are expressed as mean ± SEM of \( n = 6 \) animals per group. Statistical analysis was performed using the Student t-test, two-tailed for unpaired data (A–D) or one-way ANOVA (E) followed by the Tukey test for multiple comparisons. * \( p < 0.05 \), ** \( p < 0.01 \) different from WT.
Optical density (O.D.)

3.4. pSer129 α-Syn and Total α-Syn in G2019S KI and LRRK2 KO Mice

Immunoblot analysis was performed in the striatum of 12-month-old WT, G2019S KI and LRRK2 KO mice, to investigate whether changes in DAT levels were associated with changes in total α-syn and pSer129 α-syn levels (Figure 6). Total α-syn levels (normalized to the housekeeping gene GAPDH) were unchanged across genotypes (F2,23 = 2.93, p = 0.07), whereas pSer129 levels (Figure 6B) were almost doubled in G2019S KI mice when compared to both WT and LRRK2 KO mice (F2,23 = 4.69, p = 0.019; Figure 6B). However, only a trend towards an increase was observed when pSer129 α-syn levels were normalized to total α-syn levels since ANOVA yielded a p-value just above the limit of significance (F2,23 = 2.93, p = 0.07, Figure 6C).

α-syn immunohistochemistry was finally performed in striatal slices from 12, 18 and 23-month-old mice (Figures 7–9). ANOVA revealed a significant change of pSer129 α-syn immunoreactivity across genotypes (F2,15 = 3.916, p = 0.042; Figure 7A), and post-hoc analysis revealed a slight increase (~6%) of pSer129 α-syn immunoreactivity in 12-month-old LRRK2 KO mice compared to age-matched WT controls. Instead, no difference was found between G2019S KI and WT mice or G2019S KI and LRRK2 KO mice. Conversely,
total α-syn immunoreactivity remained unchanged across genotypes ($F_{2,15} = 2.753, p = 0.09$; Figure 7B). At 18 months, striatal pSer129 α-syn and total α-syn immunoreactivity were similar in G2019S KI and WT mice, although total α-syn trended to increase in G2019S KI mice (+14%, $t = 2.128, df = 14, p = 0.051$, Figure 8A,B). At 23 months, pSer129 α-syn staining was similar across genotypes ($F_{2,26} = 0.51, p = 0.60$; Figure 8A), whereas total α-syn levels were significantly different ($F_{2,26} = 7.735, p = 0.0023$; Figure 9B). In particular, LRRK2 KO mice showed a significant ~15% elevation in comparison to WT mice but no statistically significant difference with G2019S KI mice. Interestingly, however, G2019S KI mice showed a ~10% increase compared to WT controls, which, however, was just above the limit of significance ($p = 0.058$).

**Figure 6.** pSer129 α-synuclein levels are elevated in the striatum of 12-month-old G2019S KI mice. Western blot analysis of (A) total α-syn and (B) pSer129 α-syn levels in the striatum of 12-month-old G2019S KI and LRRK2 KO mice in comparison with age-matched WT controls. (C) pSer129 α-syn/total α-syn ratio is also shown. Data are expressed as mean ± SEM of $n = 8$ WT, $n = 10$ G2019S KI and $n = 8$ LRRK2 KO mice. Statistical analysis was performed using one-way ANOVA followed by the Tukey test for multiple comparisons. * $p < 0.05$, different from WT mice.

**Figure 7.** pSer129 α-synuclein levels are elevated in the striatum of 12-month-old LRRK2 KO mice. Immunohistochemistry was performed in striatal slices of 12-month-old G2019S KI and LRRK2 KO mice in comparison with age-matched WT mice. Optical density (O.D.) of pSer129 α-syn (A) and total α-syn (B) immunostaining was calculated. Data are expressed as mean ± SEM of $n = 6$ mice per group. Representative images were provided in the upper panels (scale bar = 100 µm). Statistical analysis was performed by ANOVA followed by the Tukey test for multiple comparisons. * $p < 0.05$ different from WT mice.
Figure 8. pSer129 and total α-synuclein levels are unchanged in the striatum of 18-month-old G2019S KI mice. Immunohistochemistry in striatal slices of 18-month-old G2019S KI mice in comparison with age-matched WT mice. Optical density (O.D.) of pSer129 α-syn (A) and total α-syn (B) immunostaining was quantified. Data are expressed as mean ± SEM of n = 8 mice per group. Representative images were provided in the upper panels (scale bar = 100 μm).

Figure 9. α-synuclein levels are elevated in the striatum of 23-month-old LRRK2 KO mice. Immunohistochemistry in the striatum of 23-month-old G2019S KI and LRRK2 KO mice in comparison with age-matched WT mice. Optical density (O.D.) of pSer129 α-syn (A) and total α-syn (B) immunostaining was quantified. Data are expressed as mean ± SEM of n = 10 WT mice, n = 8 G2019S KI mice and n = 9 LRRK2 KO mice. Representative images were provided in the upper panels (scale bar = 100 μm). Statistical analysis was performed by ANOVA followed by the Tukey test for multiple comparisons. **p < 0.01 different from WT mice.
4. Discussion

A temporal analysis of DA transporter levels and activity in relation to α-syn and pSer129 α-syn immunoreactivity was performed in the striatum of G2019S KI mice. DAT dysfunction emerged earlier than VMAT2 dysfunction (as early as age 9 months) and outlasted it. The increase of DAT and the reduction of VMAT2 levels were observed in G2019S KI mice but not mice where LRRK2 was deleted or LRRK2 kinase activity silenced, suggesting that they are related to the mutation-associated increase of LRRK2 kinase activity. Nonetheless, the abnormal DAT activity was independent of ongoing LRRK2 kinase activity since MLi-2 failed to normalize it at a dose reducing pSer1292 levels by 75% [36,44]. The most parsimonious explanation is that abnormal DAT activity ensues from permanent changes associated with chronic enhancement of LRRK2 kinase activity at the dopaminergic synapse. Nonetheless, the possibility that repeated MLi-2 administrations are necessary to normalize DAT activity needs to be tested.

Previous studies in LRRK2 mice revealed that LRRK2 modulates DAT levels and activity [14,20,45] (for a review see [46]). A dampened response of striatal DA release to DAT blockers was detected in R1441R KI mice [47], G2019S KI mice [14] and 18-month-old hG2019S rats overexpressing the transgene in the adulthood [20]. Paradoxically, here we confirm that the response in G2019S KI mice is associated with an increase of DAT protein levels and DAT velocity (Vmax) without changes in affinity for DA [14]. As it has been shown that the density of DAT expressed in plasma membranes inversely correlates with sensitivity to DAT blockers [48,49], we have speculated that the reduced sensitivity to DAT blockers might indeed reflect a greater accumulation of DAT, and possibly DAT uptake activity, at the plasma membrane. Immunohistochemistry failed to replicate the results of Western analysis since DAT immunoreactivity was non-significantly elevated in striatal slices of 12-month-old G2019S KI mice. However, it should be recalled that, despite very sensitive, indirect immunohistochemistry is not quantitative and the signal cannot be unequivocally referred to a specific protein as in Western analysis. Anyway, the lack of changes of DAT immunoreactivity would suggest that DAT changes are mild. Elevated DAT activity has been associated with cell death in vitro [30,50–52] and experimental Parkinsonism in vivo [30] due to facilitation of toxin (e.g., MPTP) entry and/or buildup of cytosolic DA resulting in the production of toxic species and oxidative stress [30,31,50,51,53]. This process might be amplified by the impairment of VMAT2 activity [28] since, consistent with the VMAT2 role in maintaining cytosolic DA concentrations within a physiological subtoxic range, deletion of VMAT2 results in DA neuron loss [31,32,54], whereas VMAT2 overexpression is neuroprotective [31,33]. The divergent nature of the time-courses of DAT and VMAT2 levels in G2019S KI mice indicates that they are not related to changes of striatal DA terminal density. Indeed, striatal TH density does not change in G2019S KI mice compared to WT controls over aging [13,14]. It is also difficult to infer whether changes in DA transporters are linked to aging or to strain differences since across-genotype and not within-genotype longitudinal design of immunoblot analysis was performed. However, DA homeostasis undergoes age-related changes in G2019S KI mice and, specifically, DA transmission appears to be elevated at 3 but not at 12 months of age [45]. Since vesicular DA release appears similar in 12-month-old WT and G2019S KI mice [14,45], the elevation of DAT activity we observed in G2019S KI mice at 12 months might explain the normalization of DA transmission observed at this age [45]. The fact the functional changes in DA uptake outlast changes in protein levels might be due to the higher sensitivity of the functional assay, since the immunoblot analysis cannot discriminate between active and inactive DAT pools. It is unlikely that dysregulation of DA homeostasis ensues in nigral DA cell loss since G2019S KI mice do not show overt nigrostriatal DA neuron or terminal degeneration during their lifespan [13,14]. Nonetheless, they show signs of synaptic dysregulation [14,35,55] and increased susceptibility to Parkinsonian toxins along with aging [40], suggesting that they can model the presymptomatic/premotor phases of the disease. In support of this view, changes in DAT and VMAT2 levels/activity in the striatum of 12-month-old G2019S KI mice were associated with an increased phosphorylation of
α-syn at Ser129, as revealed by immunoblot analysis. This can be considered an early sign of neuron demise. In fact, although the role of this posttranslational α-syn modification in neurodegeneration remains to be established [34], presynaptic pools of pSer129 α-syn unrelated to neurodegeneration have been identified [56]. Previous dual immunofluorescence analysis revealed that the increase of striatal pSer129 levels in G2019S KI mice occurs in neurons [37], consistent with the view that G2019S LRRK2 might orchestrate DAT, VMAT2, and α-syn changes within the dopaminergic synapse. The present study cannot prove a causal link between DAT and pSer129 α-syn changes or tell whether dysregulation of DA homeostasis precedes the elevation of Ser129 α-syn phosphorylation or viceversa. Both hypotheses might be proven true. In fact, partial genetic knockdown (~50%) of VMAT2 in rats has been reported to bring about impaired striatal DA transmission, nigro-striatal DA cell loss and increased pSer129 α-syn levels [32]. On the contrary, it is well known that α-syn binds to DAT [52,57–59] and that α-syn regulates DAT trafficking [58,60] and surface localization, which is key to the modulation of DA uptake and DA homeostasis. Both positive [52,61,62] and negative [57,59,63] α-syn modulations of DAT function have been reported. The positive association of DAT levels, DAT uptake and pSer129 α-syn levels in aged G2019S KI mice is consistent with a study in SH-SY5Y cells showing that pSer129 α-syn increased Vmax without changing Km of [3H]-DA uptake, suggesting that pSer129 α-syn increases DA uptake independent of DAT trafficking [62]. Therefore, although the present data cannot prove a causal link between DAT, VMAT2 and pSer129 α-syn changes, they suggest that these changes might be part of an overall (synaptic) adaptive response associated with the G2019S mutation. pSer129 α-syn immunoreactivity analysis did not confirm immunoblot data, again revealing different sensitivities of the two techniques. The discrepancy with previous immunohistochemical finding in G20919S KI mice [26] might be due to the different method of pSer129 α-syn quantification (area-of-threshold vs. optical density) and the different model used (AAV-GFP-injected vs. naïve G2019S KI mice). Immunohistochemistry, however, revealed an increase in α-syn immunoreactivity in the striatum of 23-month-old LRRK2 KO mice. This is consistent with the elevation of α-syn levels in the kidneys of 15-month-old LRRK2 KO mice [64], although no such increase was observed in the brain of these mice. Conversely, α-syn immunoreactivity was elevated in the striatum of 15-month-old LRRK1 and LRRK2 double KO mice compared to LRRK1 and LRRK2 single KO mice and WT controls [65]. In this respect, the present data would suggest that LRRK1 compensation of LRRK2 functions [65] is not lifelong and might fade at very late ages (i.e., 23 months) leaving LRRK2 function uncompensated.

5. Conclusions

We previously reported aberrant DAT and VMAT2 levels and dysfunctional DAT in 12-month-old G2019S KI mice [14]. Here, a careful time-course of DAT and VMAT2 expression/activity and α-syn immunoreactivity in G2019S KI mice up to 23 months of age was carried out. In confirming aberrant DAT and VMAT2 levels and dysfunctional DAT in 12-month-old G2019S KI mice, we show for the first time that DAT changes preceded and outlasted VMAT2 changes, and that DAT dysfunction is not sustained by ongoing LRRK2 kinase activity. Various clinical studies failed in showing changes of DAT imaging in asymptomatic LRRK2 mutant carriers [66–68]. Nonetheless, a more recent analysis performed in a significantly larger and homogeneous patient population showed a better PET ligand binding to DAT in LRRK2 G2019S non-symptomatic carriers with respect to sporadic PD patients, which has been interpreted as being due to a slower DAT decline (i.e., a reduced DA release [69]. Our data lend support to the hypothesis that better DAT signal is due to an increase in DAT availability, although the possibility that G20919S KI mice also have reduced DA levels cannot be ruled out [13,14]. Further studies are needed to explore the mechanisms by which the G2019S mutation regulates DAT function. Immunoblot analysis in the striatum of 12-month-old G2019S KI mice also confirms the elevation of pSer129 α-syn levels previously reported with immunohistochemistry [14], although a different quantification method of immunostaining can influence the outcome of
the analysis. Finally, immunohistochemical analysis extended from 12-month-old G2019S KI and WT mice [14] to 12, 18 and 23-month-old G2019S KI, LRRK2 KO and WT mice reveals for the first time a very late elevation of α-syn levels in LRRK2 KO mice, which confirms the role of LRRK2 in α-syn clearance and, more in general, proteostasis [37,65,70,71].

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/biomedicines10040881/s1, Figure S1: DAT immunoreactivity was unchanged in the striatum of 12-month-old G2019S KI mice.

**Author Contributions:** Conceptualization, D.M. and M.M.; Methodology, D.M., C.D. and F.V.; Formal Analysis, D.M., F.A., S.N., C.D. and F.V.; Investigation, D.M., C.D., F.A., S.N. and F.V.; Resources, M.M.; Writing—Original Draft Preparation, M.M.; Writing—Review and Editing, All authors; Supervision, M.M. and K.V.; Funding Acquisition, M.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the University of Ferrara, Grant No. FAR2019.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the University of Ferrara and Italian Ministry of Health (license nos. 102/2017-PR and 134/2017-PR).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Chittoor-Vinod, V.G.; Nichols, R.J.; Schule, B. Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism. *Int. J. Mol. Sci.* 2021, 22, 1045. [CrossRef] [PubMed]

2. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M.; Kawaguchi, T.; Tsunoda, T.; Watanabe, M.; Takeda, A.; et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. *Nat. Genet.* 2009, 41, 1303–1307. [CrossRef] [PubMed]

3. Cookson, M.R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. *Nat. Rev. Neurosci.* 2010, 11, 791–797. [CrossRef] [PubMed]

4. Mata, I.F.; Wedemeyer, W.J.; Farrer, M.J.; Taylor, J.P.; Gallo, K.A. LRRK2 in Parkinson’s disease: Protein domains and functional insights. *Trends Neurosci.* 2006, 29, 286–293. [CrossRef] [PubMed]

5. Greggio, E.; Jain, S.; Kingsbury, A.; Bandopadhyay, R.; Lewis, P.; Kaganovich, A.; van der Brug, M.P.; Beilina, A.; Blacknton, J.; Thomas, K.J.; et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. *Neurobiol. Dis.* 2006, 23, 329–341. [CrossRef]

6. West, A.B.; Moore, D.J.; Biskup, S.; Bugayenko, A.; Smith, W.W.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc. Natl. Acad. Sci. USA* 2005, 102, 16842–16847. [CrossRef]

7. Smith, W.W.; Pei, Z.; Jiang, H.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. *Nat. Neurosci.* 2006, 9, 1231–1233. [CrossRef]

8. Yao, C.; El Khoury, R.; Wang, W.; Byrd, T.A.; Pehek, E.A.; Thacker, C.; Zhu, X.; Smith, M.A.; Wilson-Delfosse, A.L.; Chen, S.G. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson’s disease. *Neurobiol. Dis.* 2010, 40, 73–81. [CrossRef]

9. Daher, J.P.; Abdelmotilib, H.A.; Hu, X.; Volpicelli-Daley, L.A.; Moehle, M.S.; Fraser, K.B.; Needle, E.; Chen, Y.; Steyn, S.J.; Galatsis, P.; et al. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates alpha-Synuclein Gene-induced Neurodegeneration. *J. Biol. Chem.* 2015, 290, 19433–19444. [CrossRef]

10. Lee, B.D.; Shin, J.H.; VanKampen, J.; Petrucelli, L.; West, A.B.; Ko, H.S.; Lee, Y.I.; Maguire-Zeiss, K.A.; Bowers, W.J.; Federoff, H.J.; et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. *Nat. Med.* 2010, 16, 998–1000. [CrossRef]

11. Marras, C.; Schule, B.; Munhoz, R.P.; Rogaueva, E.; Langston, J.W.; Kasten, M.; Meaney, C.; Klein, C.; Wadia, P.M.; Lim, S.Y.; et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. *Neurology* 2011, 77, 325–333. [CrossRef] [PubMed]

12. Xiong, Y.; Dawson, T.M.; Dawson, V.L. Models of LRRK2-Associated Parkinson’s Disease. *Adv. Neurobiol.* 2017, 14, 163–191. [CrossRef] [PubMed]
13. Yue, M.; Hinkle, K.M.; Davies, P.; Trushina, E.; Fiesel, F.C.; Christenson, T.A.; Schroeder, A.S.; Zhang, L.; Bowles, E.; Behrouz, B.; et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol. Dis. 2015, 78, 172–195. [CrossRef] [PubMed]

14. Longo, F.; Mercatelli, D.; Novello, S.; Arcuri, L.; Brugnoli, A.; Vincenzi, F.; Russo, I.; Berti, G.; Mabrouk, O.S.; Kennedy, R.T.; et al. Age-dependent dopaminergic transporter dysfunction and Serine129 phospho-alpha-synuclein overload in G2019S LRRK2 mice. Acta Neuropathol. Commun. 2017, 5, 22. [CrossRef] [PubMed]

15. Li, X.; Patel, J.C.; Wang, J.; Avshalumov, M.V.; Nicholson, C.; Buxbaum, J.D.; Elder, G.A.; Rice, M.E.; Yue, Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S. J. Neurosci. 2010, 30, 1788–1797. [CrossRef] [PubMed]

16. Melrose, H.L.; Dachsel, J.C.; Behrouz, B.; Lincoln, S.J.; Yue, M.; Hinkle, K.M.; Kent, C.B.; Korvatska, E.; Taylor, J.P.; Witten, L.; et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40, 503–517. [CrossRef]

17. Liu, G.; Sgobio, C.; Gu, X.; Sun, L.; Lin, X.; Yu, J.; Parisiadou, L.; Xie, C.; Sastry, N.; Ding, J.; et al. Selective expression of Parkinson’s disease-related Leucine-rich-repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Hum. Mol. Genet. 2015, 24, 5299–5312. [CrossRef]

18. Sloan, M.; Alegre-Abarrategui, J.; Potgieter, D.; Kaufmann, A.K.; Exley, R.; Delthiel, T.; Threlfell, S.; Connor-Robson, N.; Brimblecombe, K.; Wallings, R.; et al. LRRK2 BAC transgenic rats develop progressive, l-DOPA-responsive motor impairment, and deficits in dopaminergic circuit function. J. Neurosci. 2016, 25, 951–963. [CrossRef]

19. Lee, J.W.; Tapias, V.; Di Maio, R.; Greenamyre, J.T.; Cannon, J.R. Behavioral, neurochemical, and pathologic alterations in artificial genetic chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol. Aging 2015, 36, 505–518. [CrossRef]

20. Zhou, H.; Huang, C.; Tong, J.; Hong, W.C.; Liu, Y.J.; Xia, X.G. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 2011, 7, 753–761. [CrossRef]

21. Ramonet, D.; Daher, J.P.; Lin, B.M.; Stafa, K.; Kim, J.; Banerjee, R.; Westerlund, M.; Pletnikova, O.; Glauser, L.; Yang, L.; et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE 2011, 6, e18568. [CrossRef] [PubMed]

22. Chen, C.Y.; Weng, Y.H.; Chien, K.Y.; Lin, K.J.; Yeh, T.H.; Cheng, Y.P.; Lu, C.S.; Wang, H.L. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ. 2012, 19, 1623–1633. [CrossRef] [PubMed]

23. Arbez, N.; He, X.; Huang, Y.; Ren, M.; Liang, Y.; Nucifora, F.C.; Wang, X.; Pei, Z.; Tessarolo, L.; Smith, W.W.; et al. G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice. Hum. Mol. Genet. 2020, 29, 580–590. [CrossRef] [PubMed]

24. Karuppagounder, S.S.; Xiong, Y.; Lee, Y.; Lawless, M.C.; Kim, D.; Nordquist, E.; Martin, I.; Ge, P.; Brahmachari, S.; Jhaldiyal, A.; et al. LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP)-mediated neurotoxicity. J. Chem. Neuroanat. 2016, 76, 90–97. [CrossRef] [PubMed]

25. Lin, X.; Parisiadou, L.; Gu, X.L.; Wang, L.; Shim, H.; Sun, L.; Xie, C.; Long, C.X.; Yang, W.J.; Ding, J.; et al. Leucine-rich-repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s disease-related mutant alpha-synuclein. Neuron 2009, 64, 807–827. [CrossRef] [PubMed]

26. Novello, S.; Arcuri, L.; Dovero, S.; Dutheil, N.; Shimshek, D.R.; Bezard, E.; Morari, M. G2019S LRRK2 mutation facilitates alpha-synuclein neuropathy in aged mice. Neurobiol. Dis. 2018, 120, 21–33. [CrossRef]

27. Volpicielli-Daley, L.A.; Abdelmotilib, H.; Liu, Z.; Berti, G.; Mabrouk, O.S.; Kennedy, R.T.; Kent, C.B.; Korvatska, E.; Taylor, J.P.; Witten, L.; et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2015, 40, 503–517. [CrossRef]

28. Miller, G.W.; Gainetdinov, R.R.; Levey, A.I.; Caron, M.G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 1999, 20, 424–429. [CrossRef]

29. Sulzer, D.; Bogulavsky, J.; Larsen, K.E.; Behr, G.; Karatekin, E.; Kleinman, M.H.; Turro, N.; Krantz, D.; Edwards, R.H.; Greene, L.A.; et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. USA 2000, 97, 11869–11874. [CrossRef]

30. Masoud, S.T.; Vecchio, L.M.; Bergeron, Y.; Hossain, M.M.; Nguyen, L.T.; Bermejo, M.K.; Kile, B.; Sotnikova, T.D.; Siesser, W.B.; Gainetdinov, R.R.; et al. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiol. Dis. 2015, 54, 66–75. [CrossRef]

31. Caudle, W.M.; Richardson, J.R.; Wang, M.Z.; Taylor, T.N.; Guillot, T.S.; McCormack, A.L.; Colebrooke, R.E.; Di Monte, D.A.; Emson, P.C.; Miller, G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 2007, 27, 8138–8148. [CrossRef] [PubMed]

32. Bucher, M.L.; Barrett, C.W.; Moon, C.J.; Mortimer, A.D.; Burton, E.A.; Greenamyre, J.T.; Hastings, T.G. Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease. NPJ Parkinson’s Dis. 2020, 6, 34. [CrossRef] [PubMed]

33. Lohr, K.M.; Bernstein, A.I.; Stout, K.A.; Dunn, A.R.; Lazo, C.R.; Alter, S.P.; Wang, M.; Li, Y.; Fan, X.; Hess, E.J.; et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 2014, 111, 9977–9982. [CrossRef] [PubMed]
34. Oueslati, A.; Fournier, M.; Lashuel, H.A. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: Implications for Parkinson’s disease pathogenesis and therapies. Prog. Brain Res. 2010, 183, 115–145. [CrossRef]
35. Longo, F.; Russo, I.; Shimshek, D.R.; Greggio, E.; Morari, M. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to aging. Neurobiol. Dis. 2014, 71, 62–73. [CrossRef]
36. Mercatelli, D.; Bolognesi, P.; Frassinetti, M.; Pissano, C.A.; Longo, F.; Shimshek, D.R.; Morari, M. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes. Pharmacol. Res. Perspect. 2019, 7, e00484. [CrossRef]
37. Albanese, F.; Mercatelli, D.; Finetti, L.; Lamonaca, G.; Pizzi, S.; Shimshek, D.R.; Bernacchia, G.; Morari, M. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo. Neurobiol. Dis. 2021, 159, 105487. [CrossRef]
38. Hinkle, K.M.; Yue, M.; Behrouz, B.; Dachsel, J.C.; Lincoln, S.J.; Bowles, E.E.; Beeverers, J.E.; Bugger, B.; Winner, B.; Prots, I.; et al. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener. 2012, 7, 25. [CrossRef]
39. Herzig, M.C.; Kelly, C.; Persohn, E.; Theil, D.; Schweizer, T.; Hafner, T.; Stemmelen, C.; Troxler, T.J.; Schmid, P.; Danner, S.; et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 2011, 20, 4209–4223. [CrossRef]
40. Novello, S.; Mercatelli, D.; Albanese, F.; Domenicale, C.; Brugnoli, A.; D’Aversa, E.; Vantaggiato, S.; Dovero, S.; Murtaj, V.; Presotto, L.; et al. In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity. Neurobiol. Dis. 2021, 2021, 105579. [CrossRef]
41. Zhu, J.; Apparsundaram, S.; Dwoskin, L.P. Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. J. Pharmacol. Exp. Ther. 2009, 328, 931–939. [CrossRef] [PubMed]
42. Paxinos, G.; Franklin, K.B.J. The Mouse Brain in Stereotaxic Coordinates, 2nd ed.; Academic Press: San Diego, CA, USA, 2001.
43. Kluss, J.H.; Conti, M.M.; Kaganovich, A.; Bellina, A.; Melrose, H.L.; Cookson, M.R.; Mamais, A. Detection of endogenous S1292 autophosphorylation in mouse tissue as a readout for kinase activity. NPJ Parkinson's Dis. 2018, 4, 13. [CrossRef] [PubMed]
44. Sheng, Z.; Zhang, S.; Bustos, D.; Kleinheinz, T.; Le Pichon, C.E.; Dominguez, S.L.; Solanoy, H.O.; Drummond, J.; Zhang, X.; Ding, X.; et al. Ser1292 phosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 2012, 4, 164ra161. [CrossRef] [PubMed]
45. Volta, M.; Beccano-Kelly, D.A.; Paschall, S.A.; Cataldi, S.; MacIsaac, S.E.; Kuhlmann, N.; Kandgian, C.A.; Tatarnikov, I.; Fox, J.; Khinda, J.; et al. Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. eLife 2017, 6, 28377. [CrossRef]
46. Bu, M.; Farrer, M.J.; Khoshbouei, H. Dynamic control of the dopamine transporter in neurotransmission and homeostasis. NPJ Parkinson’s Dis. 2021, 7, 22. [CrossRef]
47. Li, Y.; Liu, W.; Oo, T.F.; Wang, L.; Tang, Y.; Jackson-Lewis, V.; Zhou, C.; Geghman, K.; Bogdanov, M.; Przedborski, S.; et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat. Neurosci. 2009, 12, 826–828. [CrossRef]
48. Chen, N.; Reith, M.E. Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J. Neurochem. 2007, 101, 377–388. [CrossRef]
49. Chen, N.; Reith, M.E. Substrates dissociate dopamine transporter oligomers. J. Neurochem. 2008, 105, 910–920. [CrossRef]
50. Chen, L.; Ding, Y.; Cagniard, B.; Van Laar, A.D.; Mortimer, A.; Chi, W.; Hastings, T.G.; Kang, U.J.; Zhuang, X. Unregulated cystolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 2008, 28, 425–433. [CrossRef]
51. Pifl, C.; Giros, B.; Caron, M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 1993, 13, 4246–4253. [CrossRef]
52. Lee, F.J.; Liu, F.; Pristupa, Z.B.; Niznik, H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. EASEB J. 2001, 15, 916–926.
53. Mosharov, E.V.; Larsen, K.E.; Kanter, E.; Phillips, K.A.; Wilson, K.; Schmitz, Y.; Krantz, D.E.; Kobayashi, K.; Edwards, R.H.; Sulzer, D. Interplay between cystolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62, 218–229. [CrossRef]
54. Taylor, T.N.; Caudle, W.M.; Miller, G.W. VMAT2-Deficient Mice Display Nigral and Extrnagral Pathology and Motor and Nonmotor Symptoms of Parkinson’s Disease. Parkinsons Dis. 2011, 2011, 124165. [CrossRef] [PubMed]
55. Volta, M.; Melrose, H. LRRK2 mouse models: Dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. Biochem. Soc. Trans. 2017, 45, 113–122. [CrossRef] [PubMed]
56. Weston, I.J.; Stackhouse, T.L.; Spinelli, K.J.; Boutros, S.W.; Rose, E.P.; Osterberg, V.R.; Luk, K.C.; Raber, J.; Weissman, T.A.; Unni, V.K. Genetic deletion of Polo-like kinase 2 reduces alpha-synuclein serine-129 phosphorylation in presynaptic terminals but not Lewy bodies. J. Biol. Chem. 2021, 102073. [CrossRef] [PubMed]
57. Wersinger, C.; Sidhu, A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 2003, 340, 189–192. [CrossRef]
58. Bellucci, A.; Navarrria, L.; Falarti, E.; Zaltieri, M.; Bono, F.; Collo, G.; Spillantini, M.G.; Missale, C.; Spano, P. Redistribution of DAT/alpha-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease. *PLoS ONE* 2011, 6, e27959. [CrossRef]

59. Swant, J.; Goodwin, J.S.; North, A.; Ali, A.A.; Gamble-George, J.; Chirwa, S.; Khoshbouei, H. alpha-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. *J. Biol. Chem.* 2011, 286, 43933–43943. [CrossRef]

60. Kisos, H.; Ben-Gedalya, T.; Sharon, R. The clathrin-dependent localization of dopamine transporter to surface membranes is affected by alpha-synuclein. *J. Mol. Neurosci.* 2014, 52, 167–176. [CrossRef]

61. Fountaine, T.M.; Wade-Martins, R. RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. *J. Neurosci. Res.* 2007, 85, 351–363. [CrossRef]

62. Hara, S.; Arawaka, S.; Sato, H.; Machiya, Y.; Cui, C.; Sasaki, A.; Koyama, S.; Kato, T. Serine 129 phosphorylation of membrane-associated alpha-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner. *Mol. Biol. Cell* 2013, 24, 1649–1660. [CrossRef] [PubMed]

63. Oaks, A.W.; Sidhu, A. Synuclein modulation of monoamine transporters. *FEBS Lett.* 2011, 585, 1001–1006. [CrossRef] [PubMed]

64. Tong, Y.; Yamaguchi, H.; Giaime, E.; Boyle, S.; Kopan, R.; Kelleher, R.J., 3rd; Shen, J. Loss of leucine-rich repeat kinases 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. *Proc. Natl. Acad. Sci. USA* 2010, 107, 9879–9884. [CrossRef] [PubMed]

65. Giaime, E.; Tong, Y.; Wagner, L.K.; Yuan, Y.; Huang, G.; Shen, J. Age-Dependent Dopaminergic Neuropathology and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice. *Neuron* 2017, 96, 796–807. [CrossRef] [PubMed]

66. Adams, J.R.; van Netten, H.; Schulzer, M.; Mak, E.; McKenzie, J.; Strongosky, A.; Sossi, V.; Ruth, T.J.; Lee, C.S.; Farrer, M.; et al. PET in LRRK2 mutations: Comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. *Brain* 2005, 128, 2777–2785. [CrossRef] [PubMed]

67. Isaias, I.U.; Benti, R.; Goldwurm, S.; Zini, M.; Cilia, R.; Gerundini, P.; Di Fonzo, A.; Bonifati, V.; Pezzoli, G.; Antonini, A. Striatal dopamine transporter binding in Parkinson’s disease associated with the LRRK2 Gly2019Ser mutation. *Mov. Disord.* 2006, 21, 1144–1147. [CrossRef]

68. Wile, D.J.; Agarwal, P.A.; Schulzer, M.; Mak, E.; Dinelle, K.; Shahinfard, E.; Vafai, N.; Hasegawa, K.; Zhang, J.; McKenzie, J.; et al. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: Cross-sectional studies. *Lancet Neurol.* 2017, 16, 351–359. [CrossRef]

69. Simuni, T.; Uribe, L.; Cho, H.R.; Caspell-Garcia, C.; Coffey, C.S.; Siderowf, A.; Trojanowski, J.Q.; Shaw, L.M.; Seibyl, J.; Singleton, A.; et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI): A cross-sectional study. *Lancet Neurol.* 2020, 19, 71–80. [CrossRef]

70. Albanese, F.; Domenicale, C.; Volta, M.; Morari, M. Modeling Parkinson’s disease in LRRK2 mice: Focus on synaptic dysfunction and the autophagy-lysosomal pathway. *Biochem. Soc. Trans.* 2022, 50, 621–632. [CrossRef]

71. Albanese, F.; Novello, S.; Morari, M. Autophagy and LRRK2 in the Aging Brain. *Front. Neurosci.* 2019, 13, 1352. [CrossRef]